• Metadoro
  • Products
  • News and analysis

News and analysis

Check market insights shared by our community members
16.01.2025
Delta Is Taking Off To Update Its Highs

Delta Air Lines stock rose markedly by low double digits in the first ten days of the new year. The U.S. carrier has served more than 200 million customers in 2024, when it was also recognized by J.D. Power, a leading American data analytics and consumer intelligence company, for being No. 1 in First/Business and Premium Economy Passenger Satisfaction. Travelers became more willing to spend extra money for swanky seats when meeting a high level of service. Delta is just positioning itself as the nation's premium airline. And what's more important, its Christmas quarter's earnings reportedly surpassed average analyst pool projections. Driven by stronger travel demand, smart financial management and capacity discipline, Delta business provided last three-months' profit of $1.85 per share vs $1.28 at the same period one year ago, compared to $1.75 in consensus estimates. On January 10, the airline industry leader put its future profit levels within a range between $0.70 and $1 per share in the current quarter through the end of March, while analyst expectations were focused on $0.77 cents, according to data compiled by LSEG. The starting months of each year always perform worse. It is clear that all carriers made losses in the Covid years of 2020-2022, but Delta profits only recovered into a range from $0.25 to $0.45 in the first quarter of 2023 and 2024, respectively, but Q1 profit numbers varied from $0.75 to $0.96 even in the three blessed years before the pandemic. Delta added that it is forecasting annual earnings in excess of $7.35 a share, which would be the highest in its 100-year history, based on its planned revenue growth of 7% to 9% in the March quarter from a year ago. The announcement could be compared to an adjusted profit of $6.16 a share in 2024. The company happily breaks through ticket prices' rising effects, almost undisturbed by a reduction in airline seats in the domestic market, which was peculiar for most carriers. Thus, new expectations created a fertile ground for setting new price records, even though price movements on Delta charts look most convincing among its other American rivals.

By the way, Citigroup analysts freshly updated their outlook on Delta Air Lines shares to raise their price target to $80 from the previous $77, vs the actual range around $65 per share where the stock just came after a reasonable market correction from last week's and all-time highs. Citigroup said it has included factors like higher revenue per available seat mile, projections of slightly lower fuel prices, increased taxation, a minor rise in share count, and the incorporation of fourth-quarter 2024 results into their financial model, which has projected Delta's profit at $7.49 per share in 2024 and $8.72 in 2025. Delta shares are Buy-rated at Citi, and we agree with their positive estimates in general, while keeping in mind even better price goals somewhere between $82.5 and $85.

09.01.2025
VeChain Is Suffering on Rising Borrowing Costs

VeChain (VET) has fallen 12.7% this week, trading at $0.0445, underperforming the broader cryptocurrency market. Bitcoin (BTC), the leading cryptocurrency, has declined by 5.6% to $93,220, with bearish momentum building as it approaches key support at $89,000-$91,000. This decline is largely attributed to tightening monetary conditions in the United States, which continue to weigh on risk assets. Investor confidence is further shaken by significant net outflows from spot BTC-ETFs, which lost $583 million on Wednesday, marking the second-largest single-day outflow on record.

If BTC falls below the critical support level of $89,000-$91,000, VeChain is likely to extend its losses, with prices potentially declining another 10% to $0.0400. A sustained drop in BTC could push VET even lower, towards $0.0300. Conversely, a strong rebound in BTC prices to the $100,000 level could drive VET back up to $0.0500, representing a recovery of approximately 12% from current levels.

14.01.2025
Merck Becomes Interesting to Be Added to a Portfolio

Merck & Co (MRK) stocks have shown signs of becoming a compelling buy opportunity. Over the past six months, the stock has been in a downtrend, declining 29.8% to $94.50 per share. However, since mid-November, MRK has demonstrated a reversal of momentum, rebounding by 10.0% to reach $104.87 on December 5. Following a brief pullback and consolidation period, the stock has retested the downtrend resistance and appears poised to continue its upward trajectory.

With prices currently positioned to target $110.00, this represents a potential 9-10% upside from the present levels. Setting a stop-loss at $93.50 aligns with a prudent risk management strategy, providing protection against further downside while allowing for upside potential. The recent consolidation phase further supports the case for a breakout, making this an attractive moment to consider initiating or adding to a position in MRK.

14.01.2025
Tezos Is Seen Hodling above $1.200

Tezos (XTZ) has declined slightly by 0.2% this week, trading at $1.249, following Bitcoin’s (BTC) drop to $89,158, which triggered widespread altcoin sell-offs due to concerns of a potential further decline in BTC to $80,000. However, Bitcoin managed to hold above the critical support level at $89,000-$91,000, offering some relief to the broader crypto market.

Speculation about a shift in U.S. trade policy has provided additional support to crypto assets. Reports suggest the new U.S. administration may pursue a gradual increase in tariffs rather than an abrupt hike, which could help alleviate inflationary pressures and lead to a less aggressive monetary stance from the Federal Reserve.

This development is a positive signal for the cryptocurrency market and may help Tezos maintain its position above the key support level of $1.200.

23.01.2025
Ontology Is Sliding Towards $0.2000

Ontology (ONT) is down 2.3% this week, trading at $0.2176, in line with the broader crypto market where Bitcoin (BTC) has declined 2.0% to $101,632. While the new U.S. administration has made some strides toward fairer crypto regulation, Donald Trump has remained silent on the highly anticipated issue of adding Bitcoin to U.S. federal reserves.

Market speculation is rampant, with figures like BlackRock CEO Larry Fink suggesting Bitcoin could surge to $700,000 per coin if sovereign wealth funds begin accumulating. Other forecasts predict Bitcoin reaching $250,000 by year-end. While such projections could foster optimism, the lack of decisive action or announcements regarding U.S. crypto reserves is weighing heavily on the market.

For Ontology, the situation remains bearish. Having breached the critical support at $0.2500 last week, the token is now approaching the $0.2000 level. A failure to provide clear evidence or statements about U.S. federal crypto reserve plans could see ONT fall even further, breaching the $0.2000 mark and deepening its losses.

AbbVie Has More Room for Appreciation

Shares of AbbVie pharmaceuticals hit an all-time record this week. This nearly $400 billion capitalized stock closed at $220.22 on September 11, up 4% from the previous day's performance, with an intraday high being at $221.76. The rise of the pharma sector is not as impressive as for so many cases in AI industry. On average, this process could be called rather restorative, even for big pharma stocks, but Abbvie as a real giant of the sector is a pleasant exception, having added about 30% from April's local lows corresponding to the tariff storm. And it has room for additional appreciation by market crowds and experts in the nearest 6 weeks before its scheduled quarterly earnings call on October 24.

Historically, Humira prescription drug to reduce the signs and symptoms of moderate to severe rheumatoid arthritis has been the crown jewel of AbbVie's commercial success, with its annual revenue reaching extraordinary heights around $20 billion globally. This was once Abbvie's best-selling drug, now battling severe competition from cheaper biosimilars produced by rivals since 2023. It has been reported in the mid-week, however, that no generic competition for Abbvie's currently blockbuster immunology drug Rinvoq used for similar diseases could be seen until 2037 at least. Again, the settlement with largest generic makers, which is subject to certain provisions in the U.S., is going to prevent sales erosion of Rinvoq within this 12-year timeframe, marking a 4-year extension compared to previous public estimates. Chris Schott at JP Morgan & Chase said the extension for its Rinvoq franchise gives AbbVie "years of runway on one of its key growth drivers" develop and test more now-experimental drugs ahead of any potential loss of exclusivity in the mid-2030s.

Humira is a biologic that blocks the so-called TNF (tumor necrosis factor), while Rinvoq scientifically is a JAK (Janus kinase) inhibitor that works inside cells to block signals causing inflammation. They also differ in how they are administered as Humira is an injection, whereas Rinvoq is a daily oral tablet. Rinvoq is also being tested for diseases such as alopecia areata, vitiligo, hidradenitis suppurativa and systemic lupus erythematosus. Rinvoq's annual sales for 2024 were $5.97 billion, a 46% increase from the prior year, while its Q2 2025 sales already reached $2.028 billion, another 41.8% of remarkable surplus YoY, accounting for more than 10% of total Abbvie sales. The figures contribute much to AbbVie's overall sales, with the combined sales of $15.42 billion in Q2 2025, with Rinvoq and Skyrizi projected to exceed $31 billion together by as early as 2027. Skyrizi is a brand name for a biologic injection to treat plaque psoriasis, its net sales reached $11.7 billion in 2024, a more than 50% increase vs 2023, and generated $4.4 billion only in the previous quarter to marking a 62% increase on an annual basis QoQ.

For us, the "fair value" of Abbvie could be estimated within the range of between $235 and $250 per share. We will wait and see when the opinion of the market crowd joins these reasonable estimates. This may happen before the end of this year or later in the spring of 2026, depending on investors' immediate response to the quarterly report in late October.

26
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
Litecoin Is Struggling to Push Higher

Litecoin (LTC) is adding 1.5% to $115.74 this week, underperforming Bitcoin (BTC), which is rising by 3.4% to $114,487. LTC could be preparing for stronger moves as the SEC decision on a spot LTC-ETF approaches in October. Such approvals typically attract institutional investors and increase liquidity. Expectations of a dovish Fed stance may also support momentum. However, the token remains capped by the uptrend resistance at $125–126, which it unsuccessfully attempted to break in August. The nearest target is $120, and a decisive move above that level could open the way towards $140.

24
Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
VeChain Is Building an Upside Momentum

VeChain (VET) is rising by 5.6% to $0.02470 this week, outperforming Bitcoin (BTC), which is adding 2.7% to $114,000. BTC climbed to $114,270 on Wednesday after U.S. producer price index data came in lower than expected, giving risky assets a boost. VET has closely tracked the benchmark’s move.

Now, investors are focused on U.S. consumer inflation data due Thursday. If it also surprises to the downside, BTC could extend gains toward the $117,000–$120,000 resistance zone. In that scenario, VET could finally break out of its three-month consolidation range, with upside potential first to $0.03000 and possibly further to $0.04000.

34
B
Oracle Brings More Than Enough

"Oracle shares will make me a little richer than I am now. I've nothing more to tell you. So far, they cost less than $220, not $250 and not $300". That was exactly what I told you in early July. And now the share price of Oracle is at nearly $320 after soaring by more than 32% (!) in the pre-market on Wednesday. I adore Oracle business. I also felt it was very much undervalued. But right now this is one of the most strange and barely unjustified one-off upside moves I have ever seen. So, I am fully satisfied with the current amount of profit and just take it immediately.

I don't even really care about the underlying reason behind such a crazy move, because this jump of such a giant company is too big for any kind of regular trading. I would take profits on any reason for the spike, as there will almost certainly be not only higher prices in the very near future, but also some lower pullback for re-entry after Oracle's price technical consolidation within some higher-than-before but lower-than-now range. Still, I will briefly describe to you what the point is behind this amazing price action, for those who missed it all.

The company's RPO (remaining performance obligations), which is actually an effective measure of booked revenue, surged by stratospheric 360% YoY to as much as $455 billion. The consensus number was $178 billion "only". And Oracle's CEO Safra Catz also projected “several additional multi-billion-dollar” clients to be signed in the nearest "few months". Booked revenue at Oracle's cloud infrastructure division will soon surpass half-a-trillion Dollars, the company emphasized, thanks to its relatively low-cost, artificial intelligence-powered offerings, as it is going to grow 77% to $18 billion during the current fiscal year and then reach $32 billion, $73 billion, $114 billion, and ultimately $144 billion over the next four years. Oracle is producing a range of popular AI reasoning models, such as OpenAI’s ChatGPT and xAI’s Grok, available to its customers, Safra Catz commented. This piece of news effectively offset some fell-short-of-estimates quarterly results, which was high but didn't set another record. Its EPS (earnings per share) were at $1.47 on revenue of $14.93 billion, compared with expert pool estimates of $1.48 on $15.04 billion and $1.70 per share on $15.9 in the previous brilliant quarter.

UBS analysts noted that "the scale of the backlog" with $317 billion of deals added in the previous quarter alone is "so materially above Street estimates and drives such a material upward revision" that Oracle stock "deserves to re-rate materially higher, turning Oracle into perhaps the biggest large-cap growth acceleration story in all of tech". Well, Guggenheim raised Oracle stock price target today to $375, meaning another 17% of potential surplus to $320 at the moment. But that will happen later, of course. Who knows, where the price will be tomorrow or just next week? For me, this bullish jump already gave more than enough. So, I'm happy. I'd rather hold on to the shares of other AI flagships, such as NVIDIA to feed the whole ecosystem of partners to build Oracle’s data centers , including Broadcom, whose work is dependent on graphics processing units' demand and which are still far away from achieving price goals, in my opinion.

94
1

Join our community

Share your professional and amateur observations, exchange experiences, anticipate developments

Category
All
Stocks
Crypto
Etf
Commodities
Indices
Currencies
Energies
Metals
Instruments
Author
All
Metadoro
Contributors